Company Overview and News
BARCELONA — Is natural gas a transition fuel on the road to a decarbonized future? That was the question posed to several chief executive officers (CEOs) of top energy firms at the Gastech Exhibition and Conference here on Monday.
FSGCF FGENG FGENF FGEN RDS.B RDS.A FSGCY RYDBF RDSB RDSA RYDAF
LOPEZ-LED First Gen Corp. said its offer to buy the government’s banked gas at $3.48 per gigajoules could result in savings for electricity users of close to P0.60 per kilowatt-hour (kWh)or a total of around P10 billion for the period starting next month and early 2024, the year when the Malampaya gas-to-power contract ends.
FSGCF FGENG FGENF FGEN FSGCY
ESCONDIDO, Calif., Sept. 14, 2018 (GLOBE NEWSWIRE) -- One Stop Systems, Inc. (Nasdaq: OSS), a leader in specialized high-performance computing, has introduced the world’s first PCIe Gen 4 cable adapter, the HIB68-x16.
FSGCF FGENG OSS FGENF FGEN FSGCY
LOPEZ Holdings Corp. reported a net income of P1.03 billion in the second quarter, higher by 43% compared with year ago’s P721-million profit attributable to the equity holders of the parent firm, with the stable showing of its energy unit boosting the quarterly results.
FPHPC FSGCF FGENG FGENF MER FGEN FSGCY LPZ FPHP FPH
Lopez Holdings Corp. reported a net income of P1.03 billion in the second quarter, higher by 43% compared with year ago’s P721-million profit attributable to the equity holders of the parent firm, with the stable showing of its energy unit boosting the quarterly results.
FPHPC FSGCF FGENG FGENF FGEN FSGCY LPZ FPHP FPH
It’s that time of the year again when investors commonly avoid the stock market due to the superstitious belief that the onset of the Chinese ghost festival in August may bring bad luck on their investments.
ABZPY BDOUY AEV SECB BDOUF FGENG FGENF MPCFF SPHXF SPHZF UVRBF AYAAF FSGCY MPCIY AYAAY UVRBY FSGCF ABZPF SMPH BDO FGEN ABTZY MPI SPHXY SYBJF URC ALI AP
ENERGY Development Corp. (EDC) said its board of directors had approved on Wednesday the voluntary delisting of the Lopez-led company’s common shares from the main board of the Philippine Stock Exchange (PSE).
EGDCY PSKXF FSGCY 532219 ENERGYDEV FSGCF FGENG FGENF FGEN MIC EDC PHSXY PSE
Energy Development Corp. (EDC) said its board had approved on Wednesday, Aug. 8, the voluntary delisting of the Lopez-led renewable energy company’s common shares from the main board of the Philippine Stock Exchange.
FSGCF FGENG EGDCY FGENF FGEN PSKXF FSGCY EDC PHSXY PSE 532219 ENERGYDEV
Next week, the Energy Policy Development Program (EPDP), a USAID-funded project implemented by the UP Economics Foundation, will have its last lecture and the launch of a book that incorporates conferences, lectures, and seminars the program has sponsored over the last four years.
FSGCF FGENG ABZPF FGENF FGEN FSGCY ABZPY AP
2018-06-05 rigzone - 1
MANILA, June 5 (Reuters) - Philippine fuel retailer Phoenix Petroleum said it had agreed to partner with a subsidiary of state-owned China National Offshore Oil Corp (CNOOC) to explore building a receiving terminal for liquefied natural gas in the country.
RDS.B RDS.A PSKXF FSGCY RDSB RDSA FSGCF FGENG FGENF FGEN RYDBF PHSXY PSE RYDAF
2018-05-28 bworldonline - 1
FIRST GEN Corp. is planning to invite diversified conglomerate San Miguel Corp. “within the year” to participate in its $1.2-billion liquefied natural gas (LNG) import facility, company officials said on Monday.
FSGCY SMCP1 SMGBY SMGBF FSGCF FGENG FGENF SMC2B SMC2A FGEN SMC SMC2D SMC2C SMC2F SMC2E
2018-05-28 bworldonline - 1
LOPEZ-LED First Philippine Holdings Corp. (FPH) is setting aside a budget of P22 billion for 2018, with its property development segment cornering the bulk of the capital expenditures, the company treasurer said on Monday.
FSGCF FGENG FGENF FGEN FSGCY FPH
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET